糖皮质激素在AECOPD治疗中的研究进展  

Research progress of glucocorticoid in the treatment of acute exacerbation of chronic obstructive pulmonary disease

作　　者：刘琴 肖卫[1] LIU Qin;XIAO Wei(Department of Respiratory,the First Affiliated Hospital of Yangtze University,Jingzhou 434000,Hubei,CHINA)

机构地区：[1]长江大学附属第一医院呼吸内科,湖北荆州434000

出　　处：《海南医学》2019年第1期102-105,共4页Hainan Medical Journal

摘　　要：慢性阻塞性肺疾病(COPD)是一种发病率和病死率均较高的慢性呼吸道疾病,对人类健康和社会经济产生了极大的影响。慢性阻塞性肺疾病急性加重(AECOPD)能影响患者的活动能力、精神及睡眠状态,促使病情进展,增加住院机会和病死率,并使患者容易再次急性加重。COPD病理改变的关键环节为呼吸道的慢性炎症,糖皮质激素常用于治疗AECOPD的主要药理机制是抗炎作用。现对糖皮质激素在AECOPD治疗中的疗程、给药途径、剂量及不良反应等方面的研究进展进行综述。Chronic obstructive pulmonary disease(COPD) is a chronic respiratory disease with high morbidity and mortality, which has great impact on human health and social economy. Acute exacerbation of COPD(AECOPD)can affect the activity ability, spirit and sleep of patients, promote disease progression, increase the chance of hospitalization and mortality, and make patients susceptible to acute exacerbation. Chronic inflammation of the respiratory tract is the key link of pathological changes in COPD. The main pharmacological mechanism for glucocorticosteroid in the treatment of AECOPD is anti-inflammatory. The paper reviews the research progress of glucocorticosteroid, including the duration, route, dosage, and adverse reactions.

关 键 词：糖皮质激素 慢性阻塞性肺疾病急性加重期 慢性炎症 治疗 研究进展 

分 类 号：R563[医药卫生—呼吸系统]